Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022

Q3

• Autores: Prudden, Holly J.; Achilles, Sharon L.; Schocken, Celina; Broutet, Nathalie; Canfell, Karen; Akaba, Hiroki; Basu, Partha; Bhatla, Neerja; Chirenje, Z. Mike; Delany-Moretlwe, Sinead; Denny, Lynette; Gamage, Deepa G.; Herrero, Rolando; Hutubessy, Raymond; Villa, Luisa Lina; Murillo, Raul; Schiller, John T.; Stanley, Margaret; Temmerman, Marleen; Zhao, Fanghui; Ogilvie, Gina; Kaslow, David C.; Dull, Peter; Gottlieb, Sami L.; Therapeutic HPV Vaccine PPC Expert Consultation Group
• Tipo de recurso: Article of journal
• Fecha de publicación: 2022
• Institución: Pontificia Universidad Javeriana
• Repositorio: Repositorio Universidad Javeriana
• Idioma: eng
• OAI Identifier: oai:repository.javeriana.edu.co:10554/63858
• Acceso en línea: https://www.sciencedirect.com/science/article/pii/S0264410X22009999?via%3Dihub; http://hdl.handle.net/10554/63858; https://doi.org/10.1016/j.vaccine.2022.08.020
• Palabra clave: Cervical cancer; HPV; Therapeutic HPV vaccine; Preferred product characteristics
• License: Atribución-NoComercial 4.0 Internacional